EPRX EUPRAXIA PHARMACEUTICALS INC. Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1581178 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY-51.3%
TTM EPS YoY-35.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-66.8%
ROA-63.7%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets6.6%
Debt / equity0.00x
Current ratio15.12x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.74x
Accruals ratio-16.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0 | $0 | $0 | — |
| R&D expense | $21.33M | $16.08M | $20.36M | $13.63M |
| SG&A expense | $17.10M | $10.92M | $7.48M | $3.99M |
| Interest expense | $0 | $603,573 | $1.17M | $982,856 |
| Pretax income | -$38.59M | -$25.74M | -$28.93M | -$18.99M |
| Income tax | $19,091 | $1,804 | $36,423 | $0 |
| Net income | -$38.58M | -$25.50M | -$28.22M | -$18.49M |
| EPS (basic) | -1.03 | -0.76 | -1.17 | -0.96 |
| EPS (diluted) | -1.03 | -0.76 | -1.17 | -0.96 |
| Weighted avg. shares (diluted) | 39.96M | 33.93M | 24.15M | 19.29M |
| Balance sheet | ||||
| Cash & equivalents | $80.56M | $33.10M | $19.34M | $18.26M |
| Receivables | $716,095 | $258,074 | $153,749 | — |
| Current assets | $85.10M | $34.44M | $19.80M | $18.59M |
| PP&E, net | $834,429 | $357,893 | $409,587 | $443,464 |
| Total assets | $86.15M | $34.94M | $20.27M | $19.12M |
| Current liabilities | $5.63M | $3.10M | $19.37M | $3.06M |
| Total liabilities | $5.70M | $3.10M | $19.37M | $11.91M |
| Shareholders' equity | $82.04M | $33.40M | $2.22M | $7.79M |
| Shares outstanding | 51.94M | 35.64M | 27.28M | 21.59M |
| Cash flow statement | ||||
| Operating cash flow | -$28.55M | -$29.99M | -$20.75M | -$14.40M |
| Investing cash flow | -$588,947 | -$75,159 | -$73,377 | $9.83M |
| Financing cash flow | $76.06M | $45.78M | $21.08M | $10.80M |
| Depreciation & amortization | $237,717 | $171,719 | $155,527 | $147,894 |
| Stock-based compensation | $8.76M | $3.22M | $1.41M | $1.43M |
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.